Who We Are

About Us

Committed to Accelerating Progress


Accelerate Progress is a recognized 501(c)3 public charity created to bring together the many constituencies necessary to assess, address, and improve the systems we use to develop, regulate, and use new therapies for patients fighting cancer and other life-threatening diseases.  The underpinning for much of our systems approach platform comes from the work of our Chief Scientific Advisor, Dr. Phillip Schein, who has published extensively on such issues. 

Accelerating Access Through Better Science

The formative period of Accelerate Progress has been spent assembling some of the most thoughtful scientific minds in this country to the cause.  The science of the 21st century is strong and can help us truly accelerate progress if we make better use of the tools available right now.  To that end, we’re continuing to assemble a Scientific Advisory Board that is second to none for organizations such as ours.  Dr. Schein and Dr. Emil Freireich are both past presidents of the American Society of Clinical Oncologists (ASCO), noted as respected leaders in the field of oncology.  Dr. Paul Schellhammer was most recently President of the American Urological Association (AUA), has been a prostate cancer patient himself, and leads in developing new treatment paradigms for urologic oncologists and their patients.  Ms. Barbara Scheffler brings more than 30 years of drug development experience to the Board.  Dr. Scott Gottlieb has served in various capacities at the Food and Drug Administration (FDA), having served as Senior Adviser for Medical Technology, Director of Medical Policy Development, and most recently Deputy Commissioner for Medical and Scientific Affairs. Dr. Gottlieb has also served as a senior policy adviser at the Centers for Medicare and Medicaid Services (CMS).  Both Dr. Schein and Dr. Alberts have chaired the Oncology Drug Advisory Committee for FDA.  Dr. Bertino has authored, or co-authored, over 400 scientific publications, and was the founding editor of the Journal of Clinical Oncology, one of the largest and most respect cancer research journals in the world today.  Dr. Macdonald is recognized as a top educator in Medical Oncology and a leading specialist in gastrointestinal cancer.  Dr. Logothetis has been appointed to the Board of Scientific Advisors of the NCI and is a member of the External Advisory Committee for the NCI-sponsored project to characterize the human cancer genome. All of our advisors are leaders in collaborating among colleagues in academic medicine, community physicians, and patient support and advocacy communities. 

In the interest of remaining open to the voices of all constituencies and focusing on patients’ needs, Accelerate Progress does not accept funding from companies developing pharmaceuticals, biotechnology drugs, or similar medical devices that treat life-threatening diseases.